Following reports that Moderna Inc. (MRNA) would not deliver to Germany within the set timeframe, a spokesman for the US pharmaceutical company said on Wednesday that Moderna would provide to the European Union coronavirus vaccines timeframe.
The company’s spokesman told Reuters in an email that Moderna intends to fulfil all of the quarterly delivery agreements that it has signed with the European Commission and with individual member states. It is planned that April deliveries will cover the range of doses notified to governments previously, he added.
A Business Insider article published in German cited sources from the German Ministry of Health that the delivery of up to 878,400 doses of the Moderna coronavirus vaccine scheduled for April 26 to May 2 might not happen.
When Moderna Inc. (MRNA) was asked about delivery problems, the company responded that it “does not cancel delivery shipments, but does sometimes review shipments based on the vaccine production process.”
Moderna said that no changes had been announced regarding delivery.
A Moderna spokesperson declined to elaborate on the number of doses each month for Europe. It has already been confirmed that the manufacturer will deliver 160 million units to the EU and 17 million units to the United Kingdom in 2021. This year, global pharmaceutical distribution should account for at least 700 million doses.
As vaccination programs in the member states have been slower than in the United Kingdom and the United States and coronavirus mutations spreading rapidly, it remains a significant concern that vaccines will not be readily available in Germany or the rest of the European Union.
Yesterday, Moderna Inc. () closed at $131.47, off -1.5% or $2.06. MRNA Stock found itself fluctuating between $130.21 and $135.16 through the day. There were 4.37 million shares exchanged, which is lower than its 50-day daily volume of 10.42 million shares and lower than its Year-to-date volume of 11.87 million shares. The company stock has advanced 279.53% in the past 12 months, and it has increased 10.95% in the past seven days. The stock has gained 82.72% over the last six months and 20.4% in the past three months. So far this year, the stock is up 25.84%.